Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
atai Life Sciences (ATAI) company Recognify Life Sciences has reported that its Phase IIb trial of oral compound,…
Does Gabapentin Raise Dementia Risk?
The anticonvulsant gabapentin has been linked to a significantly increased risk of developing mild cognitive impairment (MCI) or…